Asterias Biotherapeutics (AST) Starts Presentation at LD Micro Main Event
Asterias Biotherapeutics (NYSE: AST) is a clinical-stage biotechnology company focusing on developing and commercializing novel therapies in the fields of cell therapy and regenerative medicine specifically for the areas of neurology and oncology. Asterias is developing AST-VAC1, an autologous product candidate that completed phase II clinical trials for the treatment of acute myelogenous leukemia; and AST-VAC2, an allogeneic, or non-patient specific, cancer vaccine candidate designed to stimulate patient immune responses to telomerase that is in pre-clinical stage. For more information, visit the company's website at www.asteriasbiotherapeutics.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and…







